BioSpace News Archive

The global pulmonary drugs market has been the key area of focus and the most crucial market for the healthcare industry in the last couple of years.

Dr. Reddy’s Laboratories Ltd. announced the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg, a therapeutic equivalent generic version of Concerta® Extended-Release Tablets, 18 mg, 27 mg, 36 mg, and 54 mg, approved by the U.S.

Enhances ICON’s ability to offer customers integrated solutions of patient assessments at site and in-home for decentralised trials

Funding will be used to explore scalable methods of human cell preservation, transport, and re-presentation for clinical applications

Indivumed GmbH announced the expansion of its clinical network in Asia, Europe and South America including six additional, large clinical systems which are recognized for their excellence in basic and translational oncology research.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, announced that it will present at two upcoming investor conferences.

Axonics Modulation Technologies, Inc., a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, announced that Raymond W. Cohen, CEO of Axonics, will participate in the following upcoming investor conferences

Successful Pregnancy Outcomes Rose to 64% Following Treatment in BCL6-Positive Patients on Next IVF Transfer; Previous Published Success Rates on Follow-On Transfers Without Treatment Only 12%

Centogene N.V., a commercial-stage diagnostics and genetic research company, announced that its scientific publication ‘Successful application of genome sequencing in a diagnostic setting: 1,007 index cases from a clinically heterogeneous cohort’ has appeared in the European Journal of Human Genetics - one of the world’s leading medical genetic journals.

Avivagen Inc., a world leader in natural alternatives to antibiotics with its OxC-beta™ technology, has announced its unaudited financial results for the third quarter of 2020.